Janney Montgomery Scott LLC acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 3,621 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.
Other large investors also recently bought and sold shares of the company. Allworth Financial LP increased its holdings in Intra-Cellular Therapies by 104.0% in the 2nd quarter. Allworth Financial LP now owns 667 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 340 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in Intra-Cellular Therapies in the 2nd quarter worth about $46,000. Coppell Advisory Solutions Corp. bought a new stake in Intra-Cellular Therapies in the 4th quarter worth about $47,000. China Universal Asset Management Co. Ltd. increased its holdings in Intra-Cellular Therapies by 33.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 1,283 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 321 shares in the last quarter. Finally, Global Retirement Partners LLC increased its holdings in Intra-Cellular Therapies by 3,750.0% in the 1st quarter. Global Retirement Partners LLC now owns 1,540 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 1,500 shares in the last quarter. 86.94% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
ITCI has been the subject of a number of recent research reports. Cantor Fitzgerald boosted their price target on Intra-Cellular Therapies from $98.00 to $101.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley restated an “overweight” rating and set a $80.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, August 4th. StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Thursday, October 5th. They set a “hold” rating for the company. Needham & Company LLC boosted their price target on Intra-Cellular Therapies from $71.00 to $72.00 and gave the company a “buy” rating in a research note on Friday. Finally, Royal Bank of Canada cut their price target on Intra-Cellular Therapies from $77.00 to $76.00 and set an “outperform” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and an average target price of $78.67.
Insider Buying and Selling
In related news, CEO Sharon Mates sold 55,587 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $53.76, for a total value of $2,988,357.12. Following the transaction, the chief executive officer now directly owns 1,094,722 shares of the company’s stock, valued at approximately $58,852,254.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Mark Neumann sold 55,300 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $58.79, for a total transaction of $3,251,087.00. Following the sale, the executive vice president now directly owns 45,339 shares of the company’s stock, valued at approximately $2,665,479.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sharon Mates sold 55,587 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $53.76, for a total value of $2,988,357.12. Following the sale, the chief executive officer now directly owns 1,094,722 shares in the company, valued at $58,852,254.72. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.
Intra-Cellular Therapies Stock Up 5.0 %
ITCI stock opened at $54.99 on Friday. Intra-Cellular Therapies, Inc. has a twelve month low of $42.01 and a twelve month high of $67.05. The stock has a market cap of $5.28 billion, a P/E ratio of -28.49 and a beta of 1.04. The business’s 50-day moving average price is $53.38 and its 200-day moving average price is $58.84.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.17. Intra-Cellular Therapies had a negative return on equity of 28.63% and a negative net margin of 50.40%. The company had revenue of $110.80 million for the quarter, compared to analysts’ expectations of $106.45 million. During the same period in the previous year, the firm earned ($0.92) EPS. The firm’s revenue was up 99.4% compared to the same quarter last year. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -2.11 earnings per share for the current fiscal year.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
See Also
- Five stocks we like better than Intra-Cellular Therapies
- How to Invest in Communication Stocks
- Shocking uranium play that hedge funds kept hidden
- How to Invest in Grocery Stores
- Dependable dividends: Why utility stocks are on fire
- Industrial Products Stocks Investing
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
